Apceth GmbH & Co. KG
Records under this name other than the patents Apceth GmbH & Co. KG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 5 of 5 · Back to Apceth GmbH & Co. KG
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,464,806 | Genetically Modified Mesenchymal Stem Cells Expressing an Immune Response-Stimulating Cytokine to Attract And/Or Activate Immune Cells Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,434,925 | Genetically modified mesenchymal stem cell that express an exogenous cytotoxic protein Lapsed on the fee record Ended Sep 6, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 6, 2024 | USPTO record |
| US 7,998,472 | CD34 stem cell-related methods and compositions Lapsed on the fee record Ended Aug 16, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 16, 2023 | USPTO record |
| US 8,557,578 | Expansion medium for CD34-negative stem cells Lapsed on the fee record Ended Oct 15, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 15, 2021 | USPTO record |
| US 6,361,997 | Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy Term ended Term ended Feb 24, 2021 · USPTO record | Term ended | Term ended Feb 24, 2021 | USPTO record |